SG11201907034PA - Methods of treating influenza - Google Patents
Methods of treating influenzaInfo
- Publication number
- SG11201907034PA SG11201907034PA SG11201907034PA SG11201907034PA SG11201907034PA SG 11201907034P A SG11201907034P A SG 11201907034PA SG 11201907034P A SG11201907034P A SG 11201907034PA SG 11201907034P A SG11201907034P A SG 11201907034PA SG 11201907034P A SG11201907034P A SG 11201907034PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- sydney
- pct
- level
- new south
- Prior art date
Links
- 206010022000 influenza Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- 241000712461 unidentified influenza virus Species 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017900385A AU2017900385A0 (en) | 2017-02-08 | Methods of treating influenza | |
| PCT/AU2018/050085 WO2018145148A1 (en) | 2017-02-08 | 2018-02-07 | Methods of treating influenza |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907034PA true SG11201907034PA (en) | 2019-08-27 |
Family
ID=63106827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907034PA SG11201907034PA (en) | 2017-02-08 | 2018-02-07 | Methods of treating influenza |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10918623B2 (https=) |
| EP (1) | EP3579833B1 (https=) |
| JP (1) | JP7019727B2 (https=) |
| KR (1) | KR102607599B1 (https=) |
| CN (1) | CN110325187B (https=) |
| AU (1) | AU2018218179B2 (https=) |
| BR (1) | BR112019016316A2 (https=) |
| ES (1) | ES2910136T3 (https=) |
| MX (1) | MX387115B (https=) |
| RU (1) | RU2769317C2 (https=) |
| SG (1) | SG11201907034PA (https=) |
| WO (1) | WO2018145148A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR122020020745B8 (pt) | 2010-07-22 | 2023-10-31 | Gilead Sciences Inc | Composto antiviral para o tratamento de infecções por paramyxoviridae e composição farmacêutica que o compreende |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| SI3349758T1 (sl) | 2015-09-16 | 2022-08-31 | Gilead Sciences, Inc. | Postopki za zdravljenje okužb z virusom arenaviridae |
| US10682368B2 (en) | 2017-03-14 | 2020-06-16 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| AU2018262501B2 (en) | 2017-05-01 | 2020-12-10 | Gilead Sciences, Inc. | Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate |
| WO2019014247A1 (en) | 2017-07-11 | 2019-01-17 | Gilead Sciences, Inc. | COMPOSITIONS COMPRISING POLYMERASE RNA INHIBITOR AND CYCLODEXTRIN FOR THE TREATMENT OF VIRAL INFECTIONS |
| US11660307B2 (en) | 2020-01-27 | 2023-05-30 | Gilead Sciences, Inc. | Methods for treating SARS CoV-2 infections |
| JP7554841B2 (ja) | 2020-03-12 | 2024-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | １’－シアノヌクレオシドを調製する方法 |
| WO2021207049A1 (en) | 2020-04-06 | 2021-10-14 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CA3179226A1 (en) | 2020-05-29 | 2021-12-02 | Tomas Cihlar | Remdesivir treatment methods |
| AU2021296841B2 (en) | 2020-06-24 | 2025-01-23 | Gilead Sciences, Inc. | 1'-cyano nucleoside analogs and uses thereof |
| AU2021330835B2 (en) | 2020-08-24 | 2023-12-14 | Gilead Sciences, Inc. | Phospholipid compounds and uses thereof |
| SI4204421T1 (sl) | 2020-08-27 | 2024-07-31 | Gilead Sciences, Inc., | Spojine in postopki za zdravljenje virusnih okužb |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| EP4346772B1 (en) | 2021-05-26 | 2026-04-01 | Gilead Sciences, Inc. | Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs |
| AU2022328698B2 (en) | 2021-08-18 | 2025-02-20 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| CN118574614A (zh) * | 2021-11-24 | 2024-08-30 | 生物环境有限公司 | 治疗sars-cov-2感染的方法 |
| IL315102A (en) | 2022-03-02 | 2024-10-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| KR20240154646A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| PE20250419A1 (es) | 2022-03-03 | 2025-02-14 | Gilead Sciences Inc | Compuestos antivirales y metodos de elaboracion y uso de los mismos |
| JP2025508941A (ja) | 2022-03-03 | 2025-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | 抗ウイルス化合物並びにその作製及び使用方法 |
| JP2025519390A (ja) | 2022-06-06 | 2025-06-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｓａｒｓ－ｃｏｖ－２を含むウイルス感染の治療方法 |
| WO2024006376A1 (en) | 2022-06-29 | 2024-01-04 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2024173458A1 (en) | 2023-02-16 | 2024-08-22 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| IL326322A (en) | 2023-08-31 | 2026-04-01 | Gilead Sciences Inc | Antiviral compounds and methods for their production and use |
| US20250090537A1 (en) | 2023-08-31 | 2025-03-20 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| US20250099476A1 (en) | 2023-09-06 | 2025-03-27 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US20250109157A1 (en) | 2023-09-28 | 2025-04-03 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ596107A (en) | 2005-06-24 | 2013-09-27 | Biotron Ltd | Antiviral compounds and methods |
| ES2563477T3 (es) * | 2007-08-03 | 2016-03-15 | Biotron Limited | Composiciones antivirales para tratar la hepatitis C a base de 5-(1-metilpirazol-4-il)2-naftoilguanidina y 2'-C-metiladenosina o 2'-C-metilcitidina |
| KR101369584B1 (ko) * | 2011-04-19 | 2014-03-06 | 일양약품주식회사 | 페닐-이속사졸 유도체 및 그의 제조방법 |
| JP7525976B2 (ja) * | 2014-07-07 | 2024-07-31 | エリアン リミテッド ライアビリティ カンパニー | ウイルス予防治療方法及び曝露前予防キット |
| CN110870864B (zh) | 2018-08-29 | 2021-09-24 | 复旦大学 | 马来酸卡比沙明在制备抗流感病毒药物中的应用 |
-
2018
- 2018-02-07 SG SG11201907034PA patent/SG11201907034PA/en unknown
- 2018-02-07 BR BR112019016316-6A patent/BR112019016316A2/pt not_active Application Discontinuation
- 2018-02-07 KR KR1020197024919A patent/KR102607599B1/ko active Active
- 2018-02-07 ES ES18751710T patent/ES2910136T3/es active Active
- 2018-02-07 AU AU2018218179A patent/AU2018218179B2/en active Active
- 2018-02-07 JP JP2019563650A patent/JP7019727B2/ja active Active
- 2018-02-07 US US16/483,958 patent/US10918623B2/en active Active
- 2018-02-07 MX MX2019009443A patent/MX387115B/es unknown
- 2018-02-07 CN CN201880010492.9A patent/CN110325187B/zh active Active
- 2018-02-07 EP EP18751710.7A patent/EP3579833B1/en active Active
- 2018-02-07 RU RU2019126746A patent/RU2769317C2/ru active
- 2018-02-07 WO PCT/AU2018/050085 patent/WO2018145148A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP3579833A4 (en) | 2021-01-13 |
| BR112019016316A2 (pt) | 2020-03-31 |
| MX2019009443A (es) | 2019-12-16 |
| JP2020506243A (ja) | 2020-02-27 |
| CA3052503A1 (en) | 2018-08-16 |
| JP7019727B2 (ja) | 2022-02-15 |
| RU2019126746A (ru) | 2021-03-09 |
| RU2769317C2 (ru) | 2022-03-30 |
| US10918623B2 (en) | 2021-02-16 |
| CN110325187A (zh) | 2019-10-11 |
| KR20190112051A (ko) | 2019-10-02 |
| US20200093796A1 (en) | 2020-03-26 |
| AU2018218179A1 (en) | 2019-08-22 |
| ES2910136T3 (es) | 2022-05-11 |
| EP3579833A1 (en) | 2019-12-18 |
| AU2018218179B2 (en) | 2023-05-04 |
| KR102607599B1 (ko) | 2023-11-28 |
| CN110325187B (zh) | 2022-09-30 |
| WO2018145148A1 (en) | 2018-08-16 |
| RU2019126746A3 (https=) | 2021-05-28 |
| NZ755900A (en) | 2025-03-28 |
| MX387115B (es) | 2025-03-19 |
| EP3579833B1 (en) | 2022-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201811470PA (en) | Pyrazolopyrimidine derivatives as kinase inhibitor | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900021PA (en) | Methods and compositions for the treatment of cancer | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201407368VA (en) | Drug for preventing and/or treating polycystic kidney disease | |
| SG11201407536UA (en) | Topical pharmaceutical compositions comprising terbinafine and urea | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201810786RA (en) | [bis(trihydrocarbylsilyl)aminosilyl]-functionalized styrene and a method for its preparation | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201806985WA (en) | Methods and reagents for prevention and/or treatment of infection | |
| SG11201901689YA (en) | Compounds for treating diseases associated with a mitochondrial dysfonction | |
| SG11201804587QA (en) | Isoindole compounds | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201908226XA (en) | Rapamycin analog |